84163-77-9Relevant articles and documents
Synthesis of benzoisoxazole derivatives and evaluation of inhibitory potency against cholinesterase for Alzheimer's disease therapeutics
Park, Jung-Youl,Shin, Sujeong,Kim, Jae-Kwan,Park, Kyoung Chan,Park, Jeong Ho
, p. 1464 - 1471 (2016)
To improve Alzheimer's disease (AD) therapeutics, we have designed and synthesized new benzoisoxazole derivatives that are potent inhibitors of cholinesterase (acetylcholinesterase [AChE] and butyrylcholinesterase [BuChE]). Since inhibition of cholinesterase (ChE) is still considered to be one of the most effective ways of treating AD patients, many new classes of ChE inhibitors have been synthesized. To identify a new type of cholinergic drug, the benzoisoxazole moiety which is the pharmacophore moiety of Risperidone was coupled with natural antioxidants. Some benzoisoxazole derivatives (26-28 and 30) were found to effectively inhibit BuChE (IC50 50 = 8.4 ±0.1 μM). The new benzoisoxazole derivatives showing BuChE inhibitory activity represent a new class of ChE inhibitor and can be used to create novel compound derivative drugs for treating AD patients.
In silico docking studies and synthesis of new phosphoramidate derivatives of 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole as potential antimicrobial agents
Sivala, Munichandra Reddy,Chintha, Venkataramaiah,Potla, Krishna Murthy,Chinnam, Sampath,Chamarthi, Naga Raju
, p. 486 - 492 (2020)
A new class of phosphoramidate derivatives of 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole were synthesized in good to excellent yields (78–96%) by an in situ, three-step process. All the synthesized molecules were evaluated for anti-bacterial and anti-fungal activities using in?vitro and in silico methods. The results revealed that the compounds 4b, 4d, 4h, 4i, and 4j exhibited the most promising anti-bacterial activity against S. aureus, B. subtilis, K. pneumoniae, S. typhi and P. mirabilis and anti-fungal activity against A. niger and A. flavus when compared with the standard drugs Norfloxacin and Nystatin at concentrations of 25, 50, 75 and 100 μg/mL. The rest of the title compounds have shown moderate activity against all the bacterial and fungal strains. Molecular docking studies revealed that the synthesized compounds have exhibited significant binding modes with high dock scores ranging from ?7.2 to ?9.5 against 3V2B protein when compared with the standard drugs Norfloxacin (?5.8) and Nystatin (?6.6) respectively. Hence, it is suggested that the synthesized phosphoramidate derivatives of 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole will stand as the promising antimicrobial drug candidates in future.
Purification method of 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride
-
Paragraph 0029; 0034; 0035, (2021/04/10)
The invention discloses a purification method of a risperidone intermediate 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride as shown in a formula II, which is characterized by comprising the following steps: adding 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride into ethanol, adding a certain amount of water, and carrying out heating reflux until the solution is clear to obtain the risperidone intermediate 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride; and cooling the compound to a certain temperature for crystal growing, then cooling the mixture to -5 to 10 DEG C, and filtering and drying the mixture to obtain the crystal. According to the purification method of the 6-fluoro-3-(4-piperidyl)-1,2-benzoisoxazole hydrochloride, the dimer shown as the formula V can be effectively separated out, the purification yield is 85% or above, the chemical purity of a finished product can reach 99.9% or above, an amplification effect cannot be generated in large-scale production, and the process is stable.
Reformulating a Pharmacophore for 5-HT2A Serotonin Receptor Antagonists
Younkin, Jason,Gaitonde, Supriya A.,Ellaithy, Amr,Vekariya, Rakesh,Baki, Lia,Moreno, José L.,Shah, Sneha,Drossopoulos, Peter,Hideshima, Kelsey S.,Eltit, Jose Miguel,González-Maeso, Javier,Logothetis, Diomedes E.,Dukat, Malgorzata,Glennon, Richard A.
, p. 1292 - 1299 (2016/09/28)
Several pharmacophore models have been proposed for 5-HT2A serotonin receptor antagonists. These typically consist of two aromatic/hydrophobic moieties separated by a given distance from each other, and from a basic amine. Although specified distances might vary, the models are relatively similar in their general construction. Because our preliminary data indicated that two aromatic (hydrophobic) moieties might not be required for such action, we deconstructed the serotonin-dopamine antipsychotic agent risperidone (1) into four smaller structural fragments that were thoroughly examined in 5-HT2A receptor binding and functional (i.e., two-electrode voltage clamp (TEVC) and intracellular calcium release) assays. It was apparent that truncated risperidone analogues behaved as antagonists. In particular, 6-fluoro-3-(1-methylpiperidin-4-yl)benzisoxazole (4) displayed high affinity for 5-HT2A receptors (Ki of ca. 12 nM) relative to risperidone (Ki of ca. 5 nM) and behaved as a potent 5-HT2A serotonin receptor antagonist. These results suggest that multiple aromatic (hydrophobic) moieties are not essential for high-affinity 5-HT2A receptor binding and antagonist activity and that current pharmacophore models for such agents are very much in need of revision.